Abstract
According to The National Coalition for Women’s Health Research’s 10Q Report: Advancing women’s heart health through improved research, diagnosis, and treatment published in June 2011, cardiovascular disease (CVD), a term used to describe diseases of the heart or blood vessels, is the leading cause of death for women in the United States, causing more than 420,000 deaths among women annually. Experts estimate that one in two women will die of heart disease or stroke compared with one in 25 women who will die of breast cancer. Despite the fact that more women than men die each year of heart disease and that there are known sex differences in symptoms and treatment, medical treatment of women has not changed substantially nor has it resulted in appropriate research into the distinct sex differences that exist in CVD. Time is of the essence. CVD death rates are increasing for women under age 55, despite an overall decrease in death rates from CVD in recent years.
This multimedia webcast will address the challenges of clinical practice with regard to the role of female gender in the diagnosis and treatment of cardiovascular disease and to help answer questions about the 10 topics of concern in the 10Q Report. A panel of experts presents emerging evidence-based data and exercise clinical decision making by incorporating clinical cases and panel discussions.
Online Access: http://elseviercme.com/ajc/cv2 .
This CME Multimedia Activity is also available through the Web site of The American Journal of Cardiology ( www.ajconline.org/ ). Click on the CME Multimedia Activity button in the navigation bar for full access.
Author Disclosures
It is the policy of the Elsevier Office of Continuing Medical Education (EOCME) that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Sharonne N. Hayes MD, FACC, FAHA has nothing to disclose.
Carl J. Pepine, MD, MACC , has grant/research support from Amarin Corporation ; Amgen, Inc. ; Amorcyte, Inc. ; AstraZeneca ; Baxter Healthcare ; Cytori Therapeutics ; Daiichi Sankyo Company Limited ; Eli Lilly and Company ; Gambro ; Genentech ; GlaxoSmithKline ; Medtronics, Inc. ; Mesoblast Limited ; National Institutes of Health/National Heart Blood and Lung Institute ; sanofi-aventis ; and is a consultant for Amarin Corporation, Eli Lilly and Company, Mesoblast Limited, and SLACK Incorporated.
William C. Roberts, MD , is on the speaker’s bureau for Merck and Company.
Nanette K. Wenger, MD, MACC, MACP, FAHA has grant/research support from Abbott Laboratories ; Gilead Sciences, Inc.; Merck and Company ; National Heart and Blood Institute ; and Pfizer, Inc. ; and is a consultant for Abbott Women’s Advisory Board; Amgen, Inc.; AstraZeneca; Gilead Sciences; Janssen Pharmaceuticals, Inc.; Merck and Company; and Pfizer, Inc.
Planners, Managers, Reviewers: Vincent E. Friedewald, MD, Timothy Hayes, MD, Karen Overstreet, EdD, RPh, FACEHP, CCMEP, Sandy Breslow, and Jill McNair hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercials interest related to the content of this activity of any amount during the past 12 months.
Acknowledgment
This multimedia activity was peer reviewed by The American Journal of Cardiology and is sponsored by the Elsevier Office of Continuing Medical Education .
Stay updated, free articles. Join our Telegram channel
Full access? Get Clinical Tree
